Reclassifying colorectal cancer subtypes

2015 ◽  
Vol 16 (16) ◽  
pp. e591
Author(s):  
Talha Khan Burki
JAMA Oncology ◽  
2017 ◽  
Vol 3 (7) ◽  
pp. 921 ◽  
Author(s):  
Raaj S. Mehta ◽  
Reiko Nishihara ◽  
Yin Cao ◽  
Mingyang Song ◽  
Kosuke Mima ◽  
...  

2014 ◽  
Author(s):  
Yiqun Hu ◽  
Kengo Yoshida ◽  
Junko Kajimura ◽  
Seishi Kyoizumi ◽  
Yoichiro Kusunoki ◽  
...  

2018 ◽  
Vol 118 (3) ◽  
pp. e4-e4
Author(s):  
Jeong Mo Bae ◽  
Jung Ho Kim ◽  
Yoonjin Kwak ◽  
Dae-Won Lee ◽  
Yongjun Cha ◽  
...  

2019 ◽  
Vol 79 (16) ◽  
pp. 4227-4241 ◽  
Author(s):  
Yasmin Kamal ◽  
Stephanie L. Schmit ◽  
Hannah J. Hoehn ◽  
Christopher I. Amos ◽  
H. Robert Frost

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 3514-3514 ◽  
Author(s):  
S. Rim Kim ◽  
Nan Song ◽  
Greg Yothers ◽  
Patrick Gavin ◽  
Carmen Joseph Allegra ◽  
...  

3514 Background: The predictive value of tumor sidedness in colorectal cancer is currently of interest especially in metastatic setting for anti-EGFR therapy response. We tested whether intrinsic molecular subtype classification predictive of treatment benefit in stage II/III colon cancer is an independent novel marker in association with tumor sidedness. Methods: All available cases included in the NSABP/NRG C-07 trial for which we had both gene expression data and anatomical data (n=1603) were used to determine the molecular subtypes using the following classifiers; the Colorectal Cancer Assigner (CRCA), the Colon Cancer Subtypes (CCS) and the Consensus Molecular Subtypes (CMS). Frequency of tumor sidedness in each subtype and recurrence-free survival were analyzed. Results: Intrinsic subtypes were differentially distributed in right- and left-colon tumors with the exception of the stem-like or CMS4 (mesenchymal) subtype (Table 1). Sidedness was not associated with prognosis (p=0.82, HR: 1.022 [CI: 0.851-1.227]) or prediction of patients with greater benefit from oxaliplatin when combined with 5-Fu+LV (interaction p=0.484). Conclusions: Although tumor sidedness is associated with distribution of intrinsic subtypes in stage II/III colon cancer, it is not predictive of survival benefit from oxaliplatin in C-07. Support: -180868, -180822, U24-CA196067; HI13C2162; PA DOH; Sanofi-Synthelabo Clinical trial information: NCT00004931. [Table: see text]


Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 667
Author(s):  
Loretta László ◽  
Anita Kurilla ◽  
Tamás Takács ◽  
Gyöngyi Kudlik ◽  
Kitti Koprivanacz ◽  
...  

The most commonly mutated isoform of RAS among all cancer subtypes is KRAS. In this review, we focus on the special role of KRAS mutations in colorectal cancer (CRC), aiming to collect recent data on KRAS-driven enhanced cell signalling, in vitro and in vivo research models, and CRC development-related processes such as metastasis and cancer stem cell formation. We attempt to cover the diverse nature of the effects of KRAS mutations on age-related CRC development. As the incidence of CRC is rising in young adults, we have reviewed the driving forces of ageing-dependent CRC.


2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 482-482
Author(s):  
Andreas Schlicker ◽  
Garry Beran ◽  
Christine M Chresta ◽  
Gael McWalter ◽  
Alison Pritchard ◽  
...  

482 Background: Colorectal cancer (CRC) is generally stratified based on genetic and epigenetic features, such as KRAS mutation and microsatellite instability status. In order to facilitate the development of new targeted drugs and treatment regimens, it is important to redefine CRC at the molecular level by identifying subtypes that are relevant for response to targeted therapy. Methods: We applied a new unsupervised approach for iteratively stratifying tumor samples using genome-wide mRNA expression data. The resulting gene expression signatures were used to subtype CRC cell line panels and publicly available CRC tumor datasets. We employed pharmacological data on the cell line panels to link the subtypes to therapy response. Results: Starting from a gene expression dataset of 63 CRC tumor samples, we employed non-negative matrix factorization (NMF) and identified two dominant CRC subtypes. In agreement with previously published results, one of the types showed a mesenchymal and the other an epithelial-like gene expression pattern. In a second step, we applied NMF on these two dominant subtypes and further stratified them into two and three subtypes, respectively. The resulting five CRC subtypes show many differences, most notably activation of specific signaling pathways. Importantly, we recovered these five subtypes in several independent, publicly available CRC datasets. This strongly suggests that the signatures capture disease-relevant features of CRC. Furthermore, we found that the different subtypes corresponded to different cell lines in a panel of CRC cell lines. The clustered CRC cell lines displayed differential responses to a number of targeted compounds, indicating that the new CRC clusters may represent disease subtypes that of differential drug sensitivity. Conclusions: The CRC subtypes discovered using our new method offer new insights into the functional and molecular processes driving CRC. Furthermore, the evidence suggests that these subtypes may differ in activated pathway status and the response to some targeted inhibitors, indicating that targeting pathways conserved in these subtypes may provide new drug discovery opportunities.


Sign in / Sign up

Export Citation Format

Share Document